oxazoles has been researched along with Dyslipidemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, T; Fukunaga, K; Ibata, T; Imachi, H; Iwama, H; Kobayashi, T; Lyu, J; Murao, K; Sato, S; Yonezaki, K; Yoshimoto, T; Zhang, G | 1 |
| Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Wilding, JP | 1 |
| Cox, SL | 1 |
| Braileanu, GT; Ding, SY; Hansen, BC; Ito, K; Tigno, XT | 1 |
| Bouillot, A; Boullay, AB; Coste, H; Dodic, N; Donche, F; Fouchet, MH; Issandou, M; Junot, C; Magny, SD; Martin, C; Potvain, F; Walker, M | 1 |
2 review(s) available for oxazoles and Dyslipidemia
| Article | Year |
|---|---|
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution | 2005 |
1 trial(s) available for oxazoles and Dyslipidemia
| Article | Year |
|---|---|
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes | 2014 |
5 other study(ies) available for oxazoles and Dyslipidemia
| Article | Year |
|---|---|
Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.
Topics: Animals; ATP Binding Cassette Transporter 1; Benzoxazoles; Butyrates; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Glucose; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin; Insulin-Secreting Cells; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Rats; RNA, Messenger; Tyrosine | 2018 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Topics: Animals; Apolipoproteins; Blood Glucose; Body Weight; Butyrates; Cholesterol, HDL; Dyslipidemias; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver Function Tests; Macaca mulatta; Male; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Treatment Outcome | 2007 |
Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity.
Topics: Animals; Anticholesteremic Agents; Cataract; Cell Line, Tumor; Dyslipidemias; Enzyme Inhibitors; Eye; Female; Humans; Intramolecular Transferases; Liver; Male; Oxazoles; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley | 2008 |